Kriya Therapeutics Raises $100 Million for its Design, Develop and Manufacture Transformative Gene Therapies Platform

Kriya Therapeutics, a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy, announced the closing of a $100 Million Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies. Proceeds from the financing will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and oncology.

“In recent years we have seen the promise of gene therapy become a reality for the treatment of a number of devastating diseases. However, the field has been constrained by critical limitations in manufacturing technology, vector design capabilities and cost,” said Shankar Ramaswamy, M.D., Co-Founder and Chief Executive Officer of Kriya Therapeutics. “Kriya was formed with the mission of revolutionizing how gene therapies are designed, developed and produced by fully integrating advanced manufacturing technologies, computational tools and development capabilities within a single company.”

By combining advances in computer science and vector biology, Kriya is developing its SIRVE™ (System for Intelligent Rational Vector Engineering) platform for de novo vector design, sequence modification and data analysis. SIRVE is deployed to advance Kriya’s internally discovered gene therapy programs and improve first-generation products, with a goal of reducing immunogenicity and improving expression and packaging efficiency. Kriya is also developing STRIPE™ (System to Realize Improved Production Efficiency), a proprietary high-efficiency manufacturing platform integrating advances in cell line technology and upstream and downstream process to achieve exponential reductions in production costs at scale.

STRIPE is being developed at Kriya’s 51,000 square foot manufacturing facility in Research Triangle Park, North Carolina, and can support simultaneous manufacturing of multiple products from early research through commercialization. The company’s full cGMP manufacturing infrastructure is expected to be online this year.